There is detailed information about the in this Centers for Disease Control and Prevention (CDC) Outbreak and Patient Notifications article, “Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa Associated with Artificial Tears”, including this fact:
As of January 31, 2023, CDC, in partnership with state and local health departments, identified 55 patients in 12 states (CA, CO, CT, FL, NJ, NM, NY, NV, TX, UT, WA, WI) with VIM-GES-CRPA, a rare strain of extensively drug-resistant P. aeruginosa.
The CDC warnings for these EzriCare Artificial Tears eye infections include the following:
- Discontinue using EzriCare Artificial Tears pending additional guidance from CDC and FDA.
- If patients were advised to use EzriCare Artificial Tears by their healthcare provider, they should follow up with their healthcare provider for an alternative artificial tears product to use.
- Patients who used EzriCare Artificial Tears and who have signs or symptoms of an eye infection, such as discharge from the eye, eye pain or discomfort, redness of the eye or eyelid, feeling of something in the eye, increased sensitivity to light, or blurry vision, should seek timely medical care. At this time, CDC does not recommend testing of patients who have used this product and who are not experiencing any signs or symptoms of infection.
Those were taken from this February 1, 2023, CDC document, “Health Alert Network (HAN) No. 485 – Outbreak of Extensively Drug-resistant Pseudomonas aeruginosa associated with Artificial Tears”, which provides a quick overview of these EzriCare Artificial Tears eye infections.
We are investigating cases of EzriCare Artificial Tears eye infections as possible drug injury lawsuits that would be filed against Global Pharma Healthcare, the company responsible for this lubricant eye drops product.
[View article at original source]EzriCare Artificial Tears
Free Case Evaluation
Strictly Confidential, No Obligation